Publicacions en què col·labora amb Camilo Silva Frojan (10)

2024

  1. FNDC4 reduces hepatocyte inflammatory cell death via AMPKα in metabolic dysfunction-associated steatotic liver disease

    Clinical Nutrition, Vol. 43, Núm. 9, pp. 2221-2233

2023

  1. Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD

    Metabolism: Clinical and Experimental, Vol. 147

2020

  1. Ghrelin Reduces TNF-α-Induced Human Hepatocyte Apoptosis, Autophagy, and Pyroptosis: Role in Obesity-Associated NAFLD

    Journal of Clinical Endocrinology and Metabolism, Vol. 104, Núm. 1, pp. 21-37

2018

  1. Clinical usefulness of abdominal bioimpedance (ViScan) in the determination of visceral fat and its application in the diagnosis and management of obesity and its comorbidities

    Clinical Nutrition, Vol. 37, Núm. 2, pp. 580-589

2012

  1. Estudio de la utilidad de la bioimpedancia en la determinación de la grasa visceral y su aplicación en el diagnóstico y tratamiento de la obesidad y sus comorbilidades

    Anales del sistema sanitario de Navarra, Vol. 35, Núm. 1, pp. 183-184

  2. The ghrelin O-Acyltransferase-Ghrelin system reduces TNF-α-Induced apoptosis and autophagy in human visceral adipocytes

    Diabetologia, Vol. 55, Núm. 11, pp. 3038-3050

2010

  1. Association of plasma acylated ghrelin with blood pressure and left ventricular mass in patients with metabolic syndrome

    Journal of Hypertension, Vol. 28, Núm. 3, pp. 560-567

2009

  1. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes

    International Journal of Obesity, Vol. 33, Núm. 5, pp. 541-552

  2. La actividad física determinada mediante acelerometría es menor en los pacientes obesos

    Trauma, Vol. 20, Núm. 2, pp. 83-91

2007

  1. Plasma osteopontin levels and expression in adipose tissue are increased in obesity

    Journal of Clinical Endocrinology and Metabolism, Vol. 92, Núm. 9, pp. 3719-3727